FDA Rejects Novocure’s Optune Mya Application for Brain Metastases
Novocure said it received a “not approvable” letter from the FDA for its U.S. premarket application for Optune Mya, a treatment for brain metastases.
By Robb M. StewartNovocure's application for U.S. premarket approval for a treatment for brain metastases has been knocked back by the Food and Drug Administration.The Swiss company said Monday it received a "not approvable" letter from the FDA in response to its application for Optune Mya for the…